GTC Biotherapeutics Signs up Ovation as U.S. Partner in "Pharming"
Summary
The Framingham, MA-based company said today it signed an exclusive partnership with Ovation Pharmaceuticals to develop and market ATryn in the United States.ATryn is approved in Europe, and marketed there by LEO Pharma, for patients undergoing surgery who also have a rare genetic disorder that makes blood clot.GTC has already submitted part of its U.S. application to market ATryn, and plans to turn in the rest to the FDA for review before the end of September, the company said in a statement.If the FDA gives it the expedited six-month review the company has requested, the drug could be approved for sale in the U.S. before the end of March.The companies plan to develop ATryn for patients with resistance to the blood thinner heparin who undergo heart bypass surgery, as well as people with clotting associated with severe sepsis, a deadly inflammatory disease.